Xeris Biopharma Revises FY23 Revenue Outlook To $145M - $165M From $135M to $165M Vs. $149.35M Est.
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma has revised its FY23 revenue outlook to $145M - $165M, up from the previous range of $135M to $165M. The company also reduced its cash utilization range to $57M to $67M and improved its year-end cash range to $55M to $65M. Xeris expects to reach cash flow breakeven point in the fourth quarter.
August 08, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma's revised FY23 revenue outlook and reduced cash utilization could positively impact its stock price in the short term.
Xeris Biopharma's revised FY23 revenue outlook indicates a positive financial performance. The reduction in cash utilization and the expectation to reach cash flow breakeven point in Q4 also signal strong financial management. These factors could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100